全球妊娠毒血症诊断市场规模、份额、趋势和成长分析报告（2026-2034年）

妊娠毒血症诊断市场规模预计将从 2025 年的 25 亿美元成长到 2034 年的 62.2 亿美元，2026 年至 2034 年的复合年增长率为 10.66%。

由于妊娠毒血症率不断上升，以及对及时、准确诊断解决方案的需求日益增长，预计妊娠毒血症诊断市场将迎来显着增长。子痫前症是一种妊娠相关疾病，其特征是高血压和器官功能障碍，对母婴健康构成严重威胁。随着医疗专业人员致力于改善孕妇的妊娠结局，能够早期识别子痫前症的创新诊断工具的需求激增。该市场涵盖多种产品，包括血压计、生物标记检测和影像技术，这些产品有助于评估子痫前症的风险。

技术进步在塑造妊娠毒血症诊断市场中发挥关键作用，生物标记发现和就地检验的创新提高了诊断能力。能够预测妊娠毒血症发作的新型生物标记的开发正在革新产前护理方法，使医护人员能够采取预防措施并密切监测高风险患者。此外，远端医疗解决方案的整合促进了对孕妇的远距监测，确保在需要时及时介入。随着市场的不断发展，那些优先考虑研发以改善诊断解决方案的公司有望占据不断成长的市场份额。

此外，妊娠毒血症诊断市场日益受到监管趋势和临床指南的影响，这些趋势和指南旨在促进产前护理中的实证实践。随着医疗系统采用标准化的妊娠毒血症诊断和管理通讯协定，对可靠、经过验证的检验解决方案的需求将持续成长。这一趋势正在推动对旨在探索新的诊断方法和改进现有技术的研究倡议的投资。随着对母婴健康的日益关注，对能够根据个别患者需求量身定制的有效妊娠毒血症诊断的需求将不断扩大，能够根据临床需求调整产品和服务的公司将在这个重要的市场中占据优势。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球妊娠毒血症诊断市场（依检测类型划分）

• 市场分析、洞察与预测
• 血液检查
• 尿液检查
• 其他的

5. 全球妊娠毒血症诊断市场（依产品类型划分）

• 市场分析、洞察与预测
• 装置
• 消耗品

6. 全球妊娠毒血症诊断市场（以最终用户划分）

• 市场分析、洞察与预测
• 医院
• 专科诊所
• 诊断中心
• 其他的

7. 全球妊娠毒血症诊断市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers
  • Abbott Laboratories
  • Beckman Coulter
  • Becton, Dickinson And Company（BD）
  • BioMAfA（C）Rieux
  • PerkinElmer
  • Quidel Corporation
  • Sera Prognostics
  • Metabolomic Diagnostics Ltd
  • Diabetomics Inc
  • Brahms GmbH
  • The Progenix Group
  • Roche Diagnostic

The Preeclampsia Diagnostics Market size is expected to reach USD 6.22 Billion in 2034 from USD 2.50 Billion (2025) growing at a CAGR of 10.66% during 2026-2034.

The Preeclampsia Diagnostics market is poised for significant growth, driven by the increasing prevalence of preeclampsia and the need for timely and accurate diagnostic solutions. Preeclampsia, a pregnancy-related condition characterized by high blood pressure and organ dysfunction, poses serious risks to both maternal and fetal health. As healthcare providers seek to improve outcomes for pregnant women, the demand for innovative diagnostic tools that can identify preeclampsia early is surging. This market encompasses a range of products, including blood pressure monitors, biomarker tests, and imaging technologies that aid in the assessment of preeclampsia risk.

Technological advancements are playing a crucial role in shaping the Preeclampsia Diagnostics market, with innovations in biomarker discovery and point-of-care testing enhancing diagnostic capabilities. The development of novel biomarkers that can predict the onset of preeclampsia is revolutionizing the approach to prenatal care, enabling healthcare providers to implement preventive measures and closely monitor at-risk patients. Additionally, the integration of telehealth solutions is facilitating remote monitoring of pregnant women, ensuring timely interventions when necessary. As the market continues to evolve, companies that prioritize research and development to advance their diagnostic offerings will likely capture a larger share of the growing demand.

Furthermore, the Preeclampsia Diagnostics market is increasingly influenced by regulatory developments and clinical guidelines that promote evidence-based practices in prenatal care. As healthcare systems adopt standardized protocols for the diagnosis and management of preeclampsia, the demand for reliable and validated diagnostic solutions will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel diagnostic approaches and improving existing technologies. As the focus on maternal and fetal health grows, the need for effective preeclampsia diagnostics that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this critical market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Blood Tests
• Urine Analysis
• Others

By Product Type

• Instruments
• Consumables

By End User

• Hospital
• Specialty Clinics
• Diagnostic Centers
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Thermo Fisher Scientific Inc, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company BD, bioMrieux, PerkinElmer, Quidel Corporation, Sera Prognostics, Metabolomic Diagnostics Ltd, Diabetomics Inc, Brahms GmbH, The Progenix Group, Roche Diagnostic

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Blood Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Urine Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Product Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Product Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Product Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Product Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Product Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PREECLAMPSIA DIAGNOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 Siemens Healthineers
  • 9.2.4 Abbott Laboratories
  • 9.2.5 Beckman Coulter
  • 9.2.6 Becton, Dickinson And Company (BD)
  • 9.2.7 BioMAfA(C)Rieux
  • 9.2.8 PerkinElmer
  • 9.2.9 Quidel Corporation
  • 9.2.10 Sera Prognostics
  • 9.2.11 Metabolomic Diagnostics Ltd
  • 9.2.12 Diabetomics Inc
  • 9.2.13 Brahms GmbH
  • 9.2.14 The Progenix Group
  • 9.2.15 Roche Diagnostic